［1］吴珺，于水，陆爱东，等.儿童核心结合因子相关性急性髓系白血病中C-KIT基因突变分析［J］.临床儿科杂志，2019，37(3):177-181.
WU J，YU S，LU AD，et al.Analysis of C-KIT gene mutation in pediatric core binding factor acute myeloid leukemia［J］.Journal of Clinical Pediatrics，2019，37(3):177-181.
［2］SOLH M，YOHE S，WEISDORF D，et al.Core-binding factor acute myeloid leukemia：Heterogeneity，monitoring，and therapy［J］.American Journal of Hematology，2014，89(12)：1121-1131.
［3］KELLY LM，GILLILAND DG.Genetics of myeloid leukemias［J］.Annual Review of Genomics and Human Genetics，2002，3:179-198.
［4］CAIROLI R，BEGHINI A，GRILLO G，et al.Prognostic impact of c-KIT mutations in core binding factor leukemias：an Italian retrospective study［J］.Blood，2006，107(9)：3463-3468.
［5］ALNAGAR AA，MAHMOUD AA，EL GAMMAL MM，et al.Outcome of core binding factor acute myeloid leukemia by receptor tyrosine kinase mutation［J］.Clinical Lymphoma，Myeloma & Leukemia，2020，20(7)：459-467.
［6］DOHNER H，ESTEY E，GRIMWADE D，et al.Diagnosis and management of AML in adults：2017 ELN recommendations from an international expert panel［J］.Blood，2017，129(4)：424-447.
［7］SANGLE NA，PERKINS SL.Core-binding factor acute myeloid leukemia［J］.Archives of Pathology & Laboratory Medicine，2011，135(11)：1504-1509.
［8］BADR P，ELSAYED GM，ELDIN DN，et al.Detection of KIT mutations in core binding factor acute myeloid leukemia［J］.Leukemia Research Reports，2018，10：20-25.
［9］胡营涛.核心结合因子急性髓系白血病临床研究［D］.郑州：郑州大学，2018:1-69.
HU YT.Clinical study of core binding factor acute myeloid leukemia［D］.Zhengzhou：Zhengzhou University，2018:1-69.
［10］HAN SY，MROZEK K，VOUTSINAS J，et al.Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)［J］.Blood Advances，2021，5(10)：2481-2489.
［11］ROGERS HJ，WANG XQ，XIE Y，et al.Comparison of therapy-related and de novo core binding factor acute myeloid leukemia：A bone marrow pathology group study［J］.American Journal of Hematology，2020，95(7)：799-808.
［12］CHEN GF，ZHOU W，GONG D，et al.Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia［J］.Leukemia & Lymphoma，2020，61(5)：1168-1177.
［13］ZHOU W，CHEN GF，GONG D，et al.Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy：a retrospective multicenter study［J］.Leukemia & Lymphoma，2020，61(4)：820-830.
［14］NAOMI KAWASHIMA，AKIMI AKASHI，YASUNOBU NAGATA，et al.Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study［J］.Annals of Hematology，2019，98(1)：83-91.
［15］王彪，华晓莹，林榕榕，等.核心结合因子相关急性髓系白血病的缓解和预后异质性多因素分析［J］.中华内科杂志，2019，58(11):796-802.
WANG B，HUA XY，LIN RR，et al.A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia［J］.Chinese Journal of Internal Medicine，2019，58(11):796-802.
［16］FABER ZJ，CHEN X，GEDMAN AL，et al.The genomic landscape of core-binding factor acute myeloid leukemias［J］.Nature Genetics，2016，48(12)：1551-1556.
［17］DUPLOYEZ N，MARCEAU-RENAUT A，BOISSEL N，et al.Comprehensive mutational profiling of core binding factor acute myeloid leukemia［J］.Blood，2016，127(20)：2451-2459.
［18］米瑞华，陈琳，郭珍，等.TKI药物联合化疗治疗伴C-KIT突变的急性髓系白血病-M2b患者疗效及安全性分析［J］.现代肿瘤医学，2021，29(2):298-302.
MI RH，CHEN L，GUO Z，et al.Clinical efficacy and safety of tyrosine kinase inhibitors combined with chemotherapy in treatment of acute myelogenous leukemia-M2b with C-KIT mutation［J］.Modern Oncology，2021，29(2):298-302.
［19］CHEN LT，CHEN CT，JIANG WT，et al.BPR1J373，an oral multiple tyrosine kinase inhibitor，targets c-KIT for the treatment of c-KIT-driven myeloid leukemia［J］.Molecular Cancer Therapeutics，2016，15(10)：2323-2333.
［20］TARLOCK K，ALONZO TA，WANG YC，et al.Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia［J］.Clinical Cancer Research，2019，25(16)：5038-5048.
［21］OMORI I，YAMAGUCHI H，MIYAKE K，et al.D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia［J］.Experimental Hematology，2017，52：56-64.e4.
［22］AV RULINA，PV SPIRIN，VS PRASSOLOV.Activated leukemic oncogenes AML1-ETO and c-kit：Role in development of acute myeloid leukemia and current approaches for their inhibition［J］.Biochemistry(Moscow)，2010，75(13)：1650-1666.
［23］REYES-SEBASTIAN J，MONTIEL-CERVANTES LA，REYES-MALDONADO E，et al.Cell proliferation and inhibition of apoptosis are related to c-Kit activation in leukaemic lymphoblasts［J］.Hematology，2018，23(8)：486-495.
［24］RIERA L，MARMONT F，TOPPINO D，et al.Core binding factor acute myeloid leukaemia and c-KIT mutations［J］.Oncology Reports，2013，29(5)：1867-1872.
［25］QIN YZ，ZHU HH，JIANG Q，et al.Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia：a comprehensive large-scale study from a single Chinese center［J］.Leukemia Research，2014，38(12)：1435-1440.
［26］PARK SH，LEE HJ，KIM IS，et al.Incidences and prognostic impact of c-KIT，WT1，CEBPA，and CBL mutations，and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia：A multicenter study in a Korean population［J］.Annals of Laboratory Medicine，2015，35(3)：288-297.
［27］QUAN X，DENG J.Core binding factor acute myeloid leukemia：Advances in the heterogeneity of KIT，FLT3，and RAS mutations(Review)［J］.Molecular and Clinical Oncology，2020，13(2)：95-100.
［28］MOSNA F，PAPAYANNIDIS C，MARTINELLI G，et al.Complex karyotype，older age，and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up［J］.American Journal of Hematology，2015，90(6)：515-523.
［29］PRABAHRAN A，TACEY M，FLEMING S，et al.Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine［J］.European Journal of Haematology，2018，101(2)：174-184.
［30］PASCHKA P，SCHLENK RF，WEBER D，et al.Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial［J］.Leukemia，2018，32(7)：1621-1630.
［31］O′DONNELL MR，TALLMAN MS，ABBOUD CN，et al.Acute myeloid leukemia，version 3.2017，NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network，2017，15(7)：926-957.
［32］JETANI H，GARCIA-CADENAS I，NERRETER T，et al.CAR T-cells targeting FLT3 have potent activity against FLT3?ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib［J］.Leukemia，2018，32(5)：1168-1179.
［33］MEDINGER MICHAEL，PASSWEG JAKOB R.Acute myeloid leukaemia genomics［J］.British Journal of Haematology，2017，179(4)：530-542.
［34］PORT M，BOTTCHER M，THOL F，et al.Prognostic significance of FLT3 internal tandem duplication，nucleophosmin 1，and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years：a systematic review and meta-analysis［J］.Annals of Hematology，2014，93(8)：1279-1286.
［35］PATNAIK MM.The importance of FLT3 mutational analysis in acute myeloid leukemia［J］.Leukemia & Lymphoma，2018，59(10)：2273-2286.
［36］王芳，王伟，刘铭，等.KIT及其他伴随基因突变对核心结合因子相关急性髓性白血病预后的影响［J］.中华医学杂志，2020，106(3):225-229.
WANG F，WANG W，LIU M，et al.The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia［J］.Chinese Medical Journal，2020，106(3):225-229.
［37］GOEMANS BF，ZWAAN CM，MILLER M，et al.Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia［J］.Leukemia，2005，19(Suppl 1)：1536-1542.
［38］JAHN N，TERZER T，STRANG E，et al.Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication［J］.Blood Advances，2020，4(24)：6342-6352.
［39］LIU X，YE Q，ZHAO XP，et al.RAS mutations in acute myeloid leukaemia patients：A review and meta-analysis［J］.Clinica Chimica Acta，2019，489：254-260.
［40］YAMATO G，SHIBA N，YOSHIDA K，et al.ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis［J］.Genes，Chromosomes and Cancer，2017，56(5)：382-393.
［41］METZELER KLAUS H.ASXL genes and RUNX1：an intimate connection［J］.Blood，2014，124(9)：1382-1383.
［42］FENG YM，LI XP，KANIEL CASSADY，et al.TET2 function in hematopoietic malignancies，immune regulation，and DNA repair［J］.Frontiers in Oncology，2019，9：210.
［43］STEGER B，FLORO L，AMBERGER DC，et al.WT1，PRAME，and PR3 mRNA expression in acute myeloid leukemia(AML)［J］.Journal of Immunotherapy，2020，43(6)：204-215.
［44］PANUZZO C，SIGNORINO E，CALABRESE C，et al.Landscape of tumor suppressor mutations in acute myeloid leukemia［J］.Journal of Clinical Medicine，2020，9(3):802.
［45］YOON JH，KIM HJ，SHIN SH，et al.BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation：consecutive monitoring in adult patients with core-binding-factor-positive AML［J］.European Journal of Haematology，2013，91(2)：112-121.
［46］RAMPAL RAAJIT K，ALKALIN A，MADZO J，et al.DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia［J］.Blood，2014，124(21)：365.
［47］LEVIS M，TSE KF，SMITH BD,et al.A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations［J］.Blood，2001，98(3)：885-887.
［48］CIOCCIO J，CLAXTON D.Therapy of acute myeloid leukemia：therapeutic targeting of tyrosine kinases［J］.Expert Opinion on Investigational Drugs，2019，28(4)：337-349.
［49］BRANDWEIN JM，HEDLEY DW，CHOW S，et al.A phase Ⅰ/Ⅱ study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia：inhibition of Akt activation correlates with complete response［J］.Leukemia，2011，25(6)：945-952.
［50］ADVANI AS，TSE W，LI H，et al.A phase Ⅱ trial of imatinib mesylate as maintenance therapy for patients with newly diagnosed c-kit-positive acute myeloid leukemia［J］.Clinical Lymphoma，Myeloma & Leukemia，2021，21(2)：113-118.
［51］WANG YY，ZHAO LJ，WU CF，et al.C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice［J］.Proceedings of the National Academy of Sciences of the United States of America，2011，108(6)：2450-2455.
［52］MARCUCCI G，GEYER S，ZHAO J，et al.Adding KIT inhibitor dasatinib(DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor(CBF) acute myeloid leukemia(AML)：Results from CALGB 10801(alliance)［J］.Blood，2014，124(21)：8.
［53］KENNEDY VE，SMITH CC.FLT3 mutations in acute myeloid leukemia：Key concepts and emerging controversies［J］.Frontiers in Oncology，2020,10:612880.
［54］ROLLIG C，SERVE H，HUTTMANN A，et al.Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia(SORAML)：a multicentre，phase 2，randomised controlled trial［J］.The Lancet Oncology，2015，16(16)：1691-1699.
［55］MORI M，KANEKO N，UENO Y，et al.Gilteritinib，a FLT3/AXL inhibitor，shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia［J］.Investigational New Drugs，2017，35(5)：556-565.
［56］PERL AE，ALTMAN JK，CORTES J，et al.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia：a multicentre，first-in-human，open-label，phase 1-2 study［J］.The Lancet Oncology，2017，18(8)：1061-1075.
［57］PRATZ KEITH W，CHERRY MOHAMAD，JESSICA K，et al.Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia(AML)［J］.Blood，2018，132(S1)：564.
［58］LIU XL，LIU HQ，LI J，et al.Role of epigenetic in leukemia：From mechanism to therapy［J］.Chemico-Biological Interactions，2020,317:108963.
［59］SHIH AH，MEYDAN C，SHANK K，et al.Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2-and TET2-mutant acute myeloid leukemia［J］.Cancer Discovery，2017，7(5)：494-505.
［60］TZELEPIS K，DE BRAEKELEER E，ASPRIS D，et al.SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4［J］.Nature Communications，2018，9(1)：484-495.
［61］VAN DE LAGEMAAT LN，FLENLEY M，LYNCH MD，et al.CpG binding protein(CFP1) occupies open chromatin regions of active genes，including enhancers and non-CpG islands［J］.Epigenetics & Chromatin，2018，11(10)：1010-1022.
［62］HAROUN F，SOLOLA SA，NASSEREDDINE S，et al.PD-1 signaling and inhibition in AML and MDS［J］.Ann Hematol，2017，96(12):1441-1448.
［63］DAVER N，GUILLERMO D，GARCIA M，et al.Efficacy，safety，and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia：A nonrandomized，open-label，phase Ⅱstudy［J］.Cancer Discov，2019，9(3):370-383.
［64］赵金，陈琳，李钢苹，等.PD-1联合伊马替尼治疗伴c-kit突变老年急性髓系白血病致AML1-ETO融合基因转阴1例［J］.中国肿瘤临床，2020，47(23):1242.
ZHAO J，CHEN L，LI GP，et al.PD-1 combined with imatinib for the treatment of AML1-ETO in elderly acute myeloid leukemia with c-KIT mutation—The fusion gene turned negative in 1 case［J］.Chinese Journal of Clinical Oncology，2020，47(23):1242.
［65］METZELER KLAUS H，BLOOMFIELD CLARA D.Clinical relevance of RUNX1 and CBFB alterations in acute myeloid leukemia and other hematological disorders［J］.Advances in Experimental Medicine and Biology，2017，962：175-199.